MAP2K7 and neoplasm: Our rationale for investigating these latter targets include prior reports demonstrating that Wee1 is a viable therapeutic target, in combination with chemotherapy, in pre-clinical models of RMS (Stewart et al., 2017; Yohe et al., 2019), while MEK inhibition has been shown to have anti-tumor efficacy in pre-clinical FN-RMS models (Marampon et al., 2006; Yohe et al., 2018).